Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry PDF full book. Access full book title Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry by Mithun Nandy. Download full books in PDF and EPUB format.
Author: Mithun Nandy
Publisher: Springer Nature
ISBN: 981166921X
Category : Business & Economics
Languages : en
Pages : 224
Get Book Here
Book Description
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach.
Author: Mithun Nandy
Publisher: Springer Nature
ISBN: 981166921X
Category : Business & Economics
Languages : en
Pages : 224
Get Book Here
Book Description
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach.
Author: Congressional Budget Office
Publisher: Lulu.com
ISBN: 1304121445
Category : Science
Languages : en
Pages : 65
Get Book Here
Book Description
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author: Daniel Andriessen
Publisher: Routledge
ISBN: 1136386599
Category : Business & Economics
Languages : en
Pages : 453
Get Book Here
Book Description
Peter Drucker has introduced us all to the knowledge era, where knowledge is the primary resource and intangibles (intellectual capital resources and assets) are now largely recognized as the most important sources of organizations' competitive advantage. With the recognition of the importance of Intangibles comes the problem of how to properly identify them and assign them a value within the corporation. This is an area of concern in 5 fields: 1) accounting and financial reporting, 2) performance measurement and management, 3) valuation in the finance field, 4) the Human Resources field in terms of management, strategy, and planning, and 5) Intellectual Capital. Over the past eight years, over 25 methods have been proposed for the valuation of intangibles coming out of these 5 fields. In this book, Andriessen evaluates 25 existing methods of intangible valuation according to highly developed criteria. In performing his evaluations, Andriessen synthesizes the state of the art research from these fields based on extensive research. He then presents his own method for valuing intangibles, which he began developing and testing as a Senior Manager at KPMG Knowledge Advisory Services in The Netherlands. He relates six case studies in which this method was tested in actual companies, carefully reviews the results of his tests, and then concludes by offering a new and improved method for valuing intangibles in his Weightless Wealth Toolkit, a complete step-by-step process for identifying, valuing, and managing Intangibles to help managers operate successfully in the Intangible Economy.
Author: Mithun Nandy
Publisher: Taylor & Francis
ISBN: 1000875288
Category : Business & Economics
Languages : en
Pages : 210
Get Book Here
Book Description
India is the largest provider of generic drugs globally. The Indian pharmaceutical sector supplies over 50% of the global demand for various vaccines and, as a result, holds an important position in the global pharmaceutical sector. This book is a comprehensive study of pharmaceutical marketing management in the Indian context and similar growth markets. The book introduces the fast-paced and multi-faceted discipline of pharmaceutical marketing management through an in-depth discussion on the genesis and evolution of its marketing concept. Combining theory and practice, it offers a strategic approach to pharmaceutical marketing from an organizational and business perspective and explicates the practical applications of it. Richly supported by case studies, the book brings together fresh perspectives and approaches equally useful for students and professionals. This book will be of interest to academicians, advanced students, and practitioners of pharmaceutical marketing and pharmaceutical management. It will also be beneficial to those interested in business strategy, decision-making, and international marketing.
Author: Franco Malerba
Publisher: Cambridge University Press
ISBN: 1139454161
Category : Business & Economics
Languages : en
Pages : 537
Get Book Here
Book Description
This volume provides a novel way of examining innovation in sectors by proposing the framework of sectoral systems of innovation. It analyses the innovation process, the factors affecting innovation, the changing boundaries and transformation of sectors, and the determinants of the innovation performance of firms and countries in different sectors.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Stuart O. Schweitzer
Publisher: Oxford University Press
ISBN: 0190623780
Category : Business & Economics
Languages : en
Pages : 433
Get Book Here
Book Description
The pharmaceutical industry -- The biotechnology industry -- Generics and biosimilars -- The global pharmaceutical industry -- The demand for pharmaceuticals -- The demand for pharmaceuticals in major international markets -- Pharmaceutical prices -- Economic evaluation of new drugs -- Pricing pharmaceuticals in a world environment -- Pharmaceutical marketing -- Patent protection -- Drug approval process in the United States -- Pharmaceutical regulation in the European Union -- Pharmaceuticals and public policy : a look ahead
Author: OECD
Publisher: Org. for Economic Cooperation & Development
ISBN: 9789264307384
Category : Drug accessibility
Languages : en
Pages : 0
Get Book Here
Book Description
This report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing.
Author: Yaeko Mitsumori
Publisher: Springer
ISBN: 9811067902
Category : Business & Economics
Languages : en
Pages : 122
Get Book Here
Book Description
This study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d‘) inserted in the Patent Act 2005 might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents. The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India’s very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis’ Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing.
Author: Henry Wai-chung Yeung
Publisher: Cornell University Press
ISBN: 1501704265
Category : Political Science
Languages : en
Pages : 309
Get Book Here
Book Description
In Strategic Coupling, Henry Wai-chung Yeung examines economic development and state-firm relations in East Asia, focusing in particular on South Korea, Taiwan, and Singapore. As a result of the massive changes of the last twenty-five years, new explanations must be found for the economic success and industrial transformation in the region. State-assisted startups and incubator firms in East Asia have become major players in the manufacture of products with a global reach: Taiwan's Hon Hai Precision has assembled more than 500 million iPhones, for instance, and South Korea’s Samsung provides the iPhone’s semiconductor chips and retina displays.Drawing on extensive interviews with top executives and senior government officials, Yeung argues that since the late 1980s, many East Asian firms have outgrown their home states, and are no longer dependent on state support; as a result the developmental state has lost much of its capacity to steer and direct industrialization. We cannot read the performance of national firms as a direct outcome of state action. Yeung calls for a thorough renovation of the still-dominant view that states are the primary engine of industrial transformation. He stresses action by national firms and traces various global production networks to incorporate both firm-specific activities and the international political economy. He identifies two sets of dynamics in these national-global articulations known as strategic coupling: coevolution in the confluence of state, firm, and global production networks, and the various strategies pursued by East Asian firms to attain competitive positions in the global marketplace.
